2025-04-08 17:44:11
Latest Post
Godrej Properties delivers its highest ever quarterly and full year bookings
Poonawalla Fincorp Launches Shopkeeper Loan Business
Revolt Motors Expands to 200 Dealerships, Targets 400 by FY26
Sobha Ltd - Real Estate Operational Update - Q4 FY 2024-25
Lemon Tree Hotels signs a new property in DarjeelingStock Report
Parmax Pharma Ltd Q3FY22 loss at Rs. 51.80 lakhs
Posted On : 2022-02-17 17:24:36( TIMEZONE : IST )
Parmax Pharma Ltd has reported Standalone financial results for the period ended December 31, 2021.
Financial Results (Q3 FY2022) - QoQ Comparison
The company has reported total income of Rs. 2.8914 crores during the period ended December 31, 2021 as compared to Rs. 6.5670 crores during the period ended September 30, 2021.
The company has posted net profit / (loss) of Rs. -0.5180 crores for the period ended December 31, 2021 as against net profit / (loss) of Rs. 1.1406 crores for the period ended September 30, 2021.
The company has reported EPS of Rs. -1.38 for the period ended December 31, 2021 as compared to Rs. 3.05 for the period ended September 30, 2021.
| Financials | Q3 FY2022 | Q2 FY2022 | % Change |
| Total Income | ₹ 2.8914 crs | ₹6.5670 crs |  -55.97% |
| Net Profit | ₹-0.5180 crs | ₹1.1406 crs | -145.41% |
| EPS | ₹-1.38 | ₹3.05 | -145.25% |
Financial Results (Q3 FY2022) - YoY Comparison
The company has reported total income of Rs. 2.8914 crores during the period ended December 31, 2021 as compared to Rs.10.4740 crores during the period ended December 31, 2020.
The company has posted net profit / (loss) of Rs.-0.5180 crores for the period ended December 31, 2021 as against net profit / (loss) of Rs.1.5368 crores for the period ended December 31, 2020.
The company has reported EPS of Rs.-1.38 for the period ended December 31, 2021 as compared to Rs.4.11 for the period ended December 31, 2020.
| Financials | Q3 FY2022 | Q3 FY2021 | % Change |
| Total Income | ₹ 2.8914 crs | ₹10.4740 crs | -72.39% |
| Net Profit | ₹-0.5180 crs | ₹1.5368 crs | -133.71% |
| EPS | ₹-1.38 | ₹4.11 | -133.58% |
Financial Results (9 Months Ended FY2022) - YoY Comparison
The company has reported total income of Rs.11.2091 crores during the 9 Months period ended December 31, 2021 as compared to Rs.18.8787 crores during the 9 Months period ended December 31, 2020.
The company has posted net profit / (loss) of Rs.0.1874 crores for the 9 Months period ended December 31, 2021 as against net profit / (loss) of Rs.1.0576 crores for the 9 Months period ended December 31, 2020.
The company has reported EPS of Rs.0.50 for the 9 Months period ended December 31, 2021 as compared to Rs.2.83 for the 9 Months period ended December 31, 2020.
| Financials | 9 Months Ended FY2022 | 9 Months Ended FY2021 | % Change |
| Total Income | ₹11.2091 crs | ₹18.8787 crs | -40.63% |
| Net Profit | ₹0.1874 crs | ₹1.0576 crs | -82.28% |
| EPS | ₹0.50 | ₹2.83 | -82.33% |
Shares of Parmax Pharma Ltd was last trading in BSE at Rs. 49.15 as compared to the previous close of Rs. 46.90. The total number of shares traded during the day was 1500 in over 20 trades.
The stock hit an intraday high of Rs. 49.20 and intraday low of 46.90. The net turnover during the day was Rs. 71935.00.
